Peptide-Functionalized Liposomal Nanocarriers for Targeted Therapy of Liver Fibrosis and Hepatocellular Carcinoma: Design, Mechanisms, and Clinical Prospects
ACS Pharmacology & Translational Science · 13.02.2026 · 9 (2) · 307-331
DOI: 10.1021/acsptsci.5c00719 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 23.01.2026. Verfasst von Kashif Maroof und 3 weiteren Autor:innen. Beteiligte Einrichtung: SUNUM, Sabanci University Nanotechnology Research Centre, Sabanci University, Istanbul TR-34956, Turkey. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE Marie Sklodowska-Curie Actions, T?rkiye Bilimsel ve Teknolojik Arastirma Kurumu.
Abstract (Originalsprache)
Liver fibrosis and hepatocellular carcinoma (HCC) remain major global health burdens, in part due to limited drug specificity, off-target toxicity, and the complex hepatic microenvironment. Peptide-functionalized liposomal nanocarriers have emerged as a promising approach to enhance cell-selective drug delivery to activated hepatic stellate cells in fibrosis and malignant hepatocytes in HCC. This review critically examines recent progress in peptide-guided liposomal systems, focusing on design strategies, receptor-mediated targeting mechanisms, and translational considerations. Key peptide ligands, including cyclic RGD peptides targeting integrins αvβ3/αvβ5, GE11 for epidermal growth factor receptor, and transferrin receptor-binding peptides, are discussed in relation to their roles in promoting receptor-mediated endocytosis. Liposome fabrication methods and ligand conjugation chemistries are evaluated for their impact on stability, ligand presentation, and in vivo biodistribution. Preclinical evidence demonstrating improved drug accumulation, reduced fibrosis markers, and suppression of tumor growth is summarized alongside current limitations including receptor heterogeneity, extracellular matrix barriers, and manufacturing scalability. Finally, emerging directions such as stimuli-responsive and theranostic liposomes as well as combination strategies with immunomodulatory therapies are highlighted. By integrating mechanistic insight with design and translational perspectives, this review identifies key opportunities and the remaining hurdles in advancing peptide-targeted liposomal nanomedicines for liver disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- SUNUM, Sabanci University Nanotechnology Research Centre, Sabanci University, Istanbul TR-34956, Turkey.
- School of Pharmacy, Monash University Malaysia, 47500 Bandar Sunway, Selangor Darul Ehsan, Malaysia.
- Department of Chemical Engineering Faculty of Engineering, Mersin University, Mersin 33343, Turkey.
ORCID-Profile: Kashif Maroof, Rükan Genç
Förderung
- HORIZON EUROPE Marie Sklodowska-Curie Actions
- T?rkiye Bilimsel ve Teknolojik Arastirma Kurumu
Zitieren
APA
Maroof, K., Lee, R. F. S., Karacabey, P., & Genç, R. (2026). Peptide-Functionalized Liposomal Nanocarriers for Targeted Therapy of Liver Fibrosis and Hepatocellular Carcinoma: Design, Mechanisms, and Clinical Prospects. ACS Pharmacology & Translational Science, 9(2), 307-331. https://doi.org/10.1021/acsptsci.5c00719
Vancouver
Maroof K, Lee RFS, Karacabey P, Genç R. Peptide-Functionalized Liposomal Nanocarriers for Targeted Therapy of Liver Fibrosis and Hepatocellular Carcinoma: Design, Mechanisms, and Clinical Prospects. ACS Pharmacology & Translational Science. 2026;9(2):307-331. doi:10.1021/acsptsci.5c00719
BibTeX
@article{Maroof2026,
author = {Maroof, Kashif and Lee, Ronald Fook Seng and Karacabey, Pinar and Genç, Rükan},
title = {Peptide-Functionalized Liposomal Nanocarriers for Targeted Therapy of Liver Fibrosis and Hepatocellular Carcinoma: Design, Mechanisms, and Clinical Prospects},
journal = {ACS Pharmacology & Translational Science},
year = {2026},
volume = {9},
number = {2},
pages = {307--331},
doi = {10.1021/acsptsci.5c00719}
}
EUVIMED